Following the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommendation, Sera Prognostics will stop study enrollment to focus on analyzing and reporting the data. Either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis, and enrollment has been halted for efficacy.
Read MoreEpic Sciences’ 56-gene ctDNA panel, a key component of the comprehensive DefineMBC blood biopsy for metastatic breast cancer, is now covered under a Medicare program for molecular diagnostic tests.
Read MoreFunding will accelerate commercialization of Gemelli’s trio-smart® and ibs-smart® precision diagnostic tests for IBS and SIBO, and its strategies for gastrointestinal discoveries related to the microbiome
Read MoreFunding will accelerate commercial launch of DefineMBC™ and expand Epic Sciences' liquid biopsy solutions for key global oncology trials
Read MoreEpic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.
Read MoreThe agreement with MultiPlan for participation in its networks will help expand access to the PreTRM® Test to allow more timely intervention to the members accessing MultiPlan’s services through its more than 700 healthcare payers and the 1.2 million participating healthcare providers.
Read MoreEpic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.
Read MoreBiosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).
Read MoreNew Assigned Rate Further Validates the Commercial Value of the PreTRM® Test
Read MoreResults confirmed that a U.S. validated proteomics predictor could be applied in low- and middle- income countries to help address global preterm birth challenges
Read MoreSera Prognostics appoints Zhenya Lindgardt and Sandra A. J. Lawrence to its Board of Directors
Read MoreDr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company’s efforts to help address the healthcare disparities that disproportionately affect underserved communities.
Read MorePublication illustrates the power of stratifying PreTRM® testing risk at or above a threshold of twice the average population risk of spontaneous preterm birth (sPTB).
Read MorePartnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, to include distribution of a children’s book with essential prenatal healthcare information and support in the form of pregnancy/NICU “care boxes”
Read MoreSera Prognostics appoints Drs. Michael R. Foley and Paul Kearney to key positions
Read MorePublication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs. Positive impact on preterm births, neonatal intensive care admissions, overall hospital length of stay and a net $54 million reduction in total costs in the analyzed population.
Read MoreStudy demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
Read MoreSera Prognostics releases health and economic benefits analysis of its PreTRM test, and announces commercial partnership with Anthem, Inc.
Read MoreSera Prognostics said on Thursday that it has closed a $100 million Series E financing round.
The round was led by existing investors Anthem and Blue Ox Healthcare Partners, with participation from Vivo Capital, aMoon Fund, and Parian Global. In conjunction with the round, Anthem Chief Analytics Officer Marcus Wilson, Anthem VP of Emerging Markets and Partnerships Elizabeth Canis, and Vivo Capital Managing Director Joe Siletto have joined Sera's board.
Read More
